Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity
The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
1. A therapeutic or prophylactic agent for the treatment or prevention of fatty liver disease, comprising a compound represented by the Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
a ring A represents a benzene ring and forms a naphthyl group with adjacent benzene ring;
X represents —O—CO— group;
Y represents a single bond, —NH— group, —CH 2 —O— group, —CH 2 — group, or —CH(NH—Boc)—CH 2 — group;
Z represents a hydrogen atom;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted cycloalkyl group, or a group represented by the following Formula (II):
wherein rings B and C independently represent an optionally substituted aryl group, an optionally substituted heterocyclic group, or an optionally substituted cycloalkyl group, and R 7 represents a single bond, —O— group, —CO— group, —NH— group, —SO 2 — group, —CO—NH— group, an optionally substituted C 1-3 alkylene group, an optionally substituted C 2-3 alkenylene group, —S—R 8 — group wherein R 8 represents an optionally substituted C 1-2 alkylene group, —CO—R 8 — group, —O—R 8 — group, or —SO 2 —R 8 —group, and Y is attached to any of the ring B, ring C, and R 7 ; and
R 3 represents 0 to 4 identical or different substituents.
2. The therapeutic or prophylactic agent according to claim 1 , wherein the fatty liver disease is non-alcoholic steatohepatitis.
3. The therapeutic or prophylactic agent according to claim 1 , wherein m is 1 and n is 0.
4. The therapeutic or prophylactic agent according to claim 1 , wherein R 2 represents an optionally substituted polycyclic aryl group or an optionally substituted polycyclic heterocyclic group.
5. The therapeutic or prophylactic agent according to claim 1 , wherein Y represents a single bond, —CH 2 — group, or —CH 2 —O— group.
6. The therapeutic or prophylactic agent according to claim 1 , wherein R 1 represents a hydrogen atom.
7. The therapeutic or prophylactic agent according to claim 1 , further comprising an active ingredient of at least one additional drug for the treatment or prevention of fatty liver disease.
8. A method of treating or preventing fatty liver disease, comprising administering the therapeutic or prophylactic agent according to claim 1 , in combination with at least one additional drug for the treatment or prevention of fatty liver disease.
9. A therapeutic or prophylactic agent for the treatment or prevention of obesity, comprising a compound represented by the Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
a ring A represents a benzene ring and forms a naphthyl group with adjacent benzene ring;
X represents —O—CO— group;
Y represents a single bond, —NH— group, CH 2 —O— group, —CH 2 — group, or —CH(NH—Boc)—CH 2 — group;
Z represents a hydrogen atom;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted cycloalkyl group, or a group represented by the following Formula (II):
wherein rings B and C independently represent an optionally substituted aryl group, an optionally substituted heterocyclic group, or an optionally substituted cycloalkyl group, and R 7 represents a single bond, —O— group, —CO— group, —NH— group, —SO 2 — group, —CO—NH— group, an optionally substituted C 1-3 alkylene group, an optionally substituted C 2-3 alkenylene group, —S—R 8 — group wherein R 8 represents an optionally substituted C 1-2 alkylene group, —CO—R 8 — group, —O—R 8 — group, or —SO 2 —R 8 — group, and Y is attached to any of the ring B, ring C, and R 7 ; and
R 3 represents 0 to 4 identical or different substituents.
10. The therapeutic or prophylactic agent according to claim 9 , wherein m is 1 and n is 0.
11. The therapeutic or prophylactic agent according to claim 9 , wherein R 2 represents an optionally substituted polycyclic aryl group or an optionally substituted polycyclic heterocyclic group.
12. The therapeutic or prophylactic agent according to claim 9 , wherein Y represents a single bond, —CH 2 — group, or —CH 2 —O— group.
13. The therapeutic or prophylactic agent according to claim 9 , wherein R 1 represents a hydrogen atom.
14. The therapeutic or prophylactic agent according to claim 9 , further comprising an active ingredient of at least one additional drug for the treatment or prevention of obesity.
15. A method of treating or preventing obesity, comprising administering the therapeutic or prophylactic agent according to claim 9 in combination with at least one additional drug for the treatment or prevention of obesity.